Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biostem Technologies Inc (OP: BSEM )

9.800 UNCHANGED
Streaming Delayed Price Updated: 2:02 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.800
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 9.800
Today's Range 9.800 - 9.800
52wk Range 1.948 - 15.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioStem Technologies Innovative Wound-Care Treatments Steepen Its Growth Trajectory ($BSEM)
Via AB Newswire
Exposures Product Safety
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments ($BSEM)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property Product Safety

Performance

YTD
+61.32%
+61.32%
1 Month
-15.15%
-15.15%
3 Month
+38.89%
+38.89%
6 Month
+2.08%
+2.08%
1 Year
+279.84%
+279.84%

More News

Read More
BioStem Technologies Announces Opening of First Clinical Site for Diabetic Foot Ulcer Study
Via ACCESSWIRE
BioStem Technologies to Highlight Core Advanced Wound Care Portfolio at SAWC Fall 2023 Conference
Via ACCESSWIRE
BioStem Technologies: CMS Decision a “Win For Patients”
Via ACCESSWIRE
BioStem Receives IRB Approval for Clinical Study to Evaluate Vendaje(R) in Diabetic Foot Ulcers
Via ACCESSWIRE
BioStem Technologies Initiates Nationwide Launch of AmnioWrap2(TM) with Venture Medical
Via ACCESSWIRE
BioStem Technologies Engages PCG Advisory for Strategic Investor Relations
Via ACCESSWIRE
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
From NovaBay Pharmaceuticals, Inc.
Via Business Wire
How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond
Via Benzinga
2022 Year in Review: BioStem Technologies Looks Back At A Year of Growth And Expansion
Via Benzinga
BioStem Technologies Announces Partnership with Kill Cliff FC
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference
From BioStem Technologies, Inc.
Via GlobeNewswire
BioStem Technologies (OTCMKTS: BSEM) Coverage Initiated at Zacks Investment Research
Via Benzinga
EXCLUSIVE: BioStem Technologies Reports Q1 Net Revenue Up 211% YoY
Via Benzinga
Cannabis Movers & Shakers: Halo Collective, Suite 420 Access, OWP, BioStem, Chicago Atlantic Advisors, Silo Wellness
Via Benzinga
Topics Cannabis
Exposures Cannabis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.